Verve Therapeutics Stock Soars as Eli Lilly Buys Gene-Editing Firm for $1.3B
Shares of Verve Therapeutics soared 75% Tuesday as Eli Lilly said it would acquire the gene-editing startup.
The deal values Verve at about $1.3 billion, with some of Eli Lilly's potential payments dependent on certain trial milestones.
Verve has an early stage clinical trial of a treatment to lower cholesterol and treat cardiovascular conditions.Shares of Verve Therapeutics (VERV) skyrocketed 75% Tuesday morning after Eli Lilly (LLY) announced that it would acquire the gene-editing startup for about $1.3 billion.
Eli Lilly said it will pay $10.50 per share to Verve shareholders initially, with a $3-per-share contingent value right (CVR) potentially paid out if Verve treats at least one patient with gene-editing medicine VERVE-102 for atherosclerotic cardiovascular disease (ASCVD) in a Phase 3 clinical trial within a decade of the deal's closing or termination of the CVR. The transaction is expected to close in the third quarter this year.
VERVE-102 currently "is being evaluated in a Phase 1b clinical trial study and has been granted Fast Track designation by the U.S. Food and Drug Administration," Lilly said.
"Verve was founded with one mission in mind: transform the treatment of cardiovascular disease from chronic care to a one-dose future," Verve CEO Dr. Sekar Kathiresan said. "In just seven years, our team has progressed three in vivo gene editing products, with two currently in the clinic. Now, we will take the next steps in the drug development journey together with an ideal strategic partner in Lilly."
The Financial Times reported late Monday that the companies were close to a deal.
Eli Lilly shares, which entered Tuesday up roughly 5% this year, were down less than 1% in recent trading. With today's sharp gains, Verve stock has nearly doubled in 2025.
UPDATE—This article has been updated with the latest share price information.
Read the original article on Investopedia
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
7 hours ago
- Associated Press
Wisner Baum: Ninth Circuit Affirms Actos RICO Class Action Certification Against Takeda and Eli Lilly
Appellate Court upholds decision in first-ever non-settlement national RICO class action lawsuit certified against a major pharmaceutical company, with potential damages exceeding $7 billion. SAN FRANCISCO, June 18, 2025 /PRNewswire/ -- The U.S. Court of Appeals for the Ninth Circuit affirmed a class certification order in Painters & Allied Trades District Council 82 Health Care Fund v. Takeda Pharmaceutical Company Limited, marking a watershed moment in a first-of-its-kind class action that is now in its eleventh year. The Ninth Circuit upheld the certification of a national class of third-party payers seeking damages under the Racketeer Influenced and Corrupt Organizations (RICO) Act against pharmaceutical giants Takeda Pharmaceutical Company and Eli Lilly and Company. The suit accuses both companies of conspiring to conceal the bladder cancer risks associated with the diabetes drug Actos (pioglitazone) for over a decade, exposing millions of vulnerable diabetics to a carcinogen without their consent. It is a legacy of fraud, attorneys say, and this ruling finally paves the way for a jury trial on this important case. The case is the first non-settlement national RICO class action lawsuit certified against a major pharmaceutical company. Legal experts estimate the total damages could exceed $7 billion. Important Legal Precedent The Ninth Circuit's affirmation comes despite opposition from the pharmaceutical defendants and industry amici, who challenged the district court's class certification on multiple grounds. In a detailed memorandum, the appellate court rejected each of the defendants' arguments, finding that the lower court 'properly conducted a 'rigorous analysis,' as required to certify a class,' and adding that it 'did not abuse its discretion by finding the predominance requirement satisfied.' The case stems from allegations that Takeda and Eli Lilly engaged in a decade-long conspiracy to conceal Actos's significant bladder cancer risks. Internal documents revealed Takeda and Lilly knew about the bladder cancer risk as early as 1999. After the FDA mandated a bladder cancer warning for Actos in 2011, drug sales dropped by 80%, demonstrating the material impact of the fraud. Plaintiffs allege the companies knew about the bladder cancer risks but chose to hide them to protect billions in annual sales, defrauding third-party payers who paid for the medication. Statement from Lead Counsel 'We are in our eleventh year litigating this case and are eager to finally get this case to trial,' said R. Brent Wisner, managing partner of Wisner Baum LLP and national class counsel. 'The evidence in this case is crystal clear: The class was deceived into purchasing billions of dollars of Actos by Takeda and Lilly whose actions plainly violated civil RICO, and exposed millions of diabetics to a carcinogen without their consent or knowledge. It's been a long and hard-fought journey, but the magnitude of this precedent and the potential impact on all pharmaceutical manufacturers was worth it. It seems perseverance is the number one determinant of success in the end. We are ready to tell this story to a jury and recoup the billions Takeda and Lilly pilfered from our clients and all those similarly situated.' What's Next With class certification affirmed, Wisner hopes that a trial date will be set for 2026. The class will seek to prove their allegations and recover treble damages under RICO's enhanced penalty provisions. Wisner Baum LLP, along with co-counsel Christopher L. Coffin of Pendley, Baudin & Coffin, LLP, serves as national class counsel. The case is Painters & Allied Trades District Council 82 Health Care Fund v. Takeda Pharmaceutical Company Limited, No. 23-55742 (9th Cir. 2025), District Court Case No. 2:17-cv-07223-JWH-AS (C.D. Cal.) Media Contact: Diana McKinley (310) 207 -3233 [email protected] The award-winning law firm of Wisner Baum has successfully litigated cases against many of the largest pharmaceutical companies in the world. Since 1985, the firm has earned a reputation for breaking new legal ground, holding corporations accountable, influencing public policy, and raising public awareness on important safety issues. Across all areas of practice, the firm has won more than $4 billion in settlements and verdicts. View original content to download multimedia: SOURCE Wisner Baum
Yahoo
8 hours ago
- Yahoo
Verve Therapeutics Stock Soars as Eli Lilly Buys Gene-Editing Firm for $1.3B
Shares of Verve Therapeutics soared 75% Tuesday as Eli Lilly said it would acquire the gene-editing startup. The deal values Verve at about $1.3 billion, with some of Eli Lilly's potential payments dependent on certain trial milestones. Verve has an early stage clinical trial of a treatment to lower cholesterol and treat cardiovascular of Verve Therapeutics (VERV) skyrocketed 75% Tuesday morning after Eli Lilly (LLY) announced that it would acquire the gene-editing startup for about $1.3 billion. Eli Lilly said it will pay $10.50 per share to Verve shareholders initially, with a $3-per-share contingent value right (CVR) potentially paid out if Verve treats at least one patient with gene-editing medicine VERVE-102 for atherosclerotic cardiovascular disease (ASCVD) in a Phase 3 clinical trial within a decade of the deal's closing or termination of the CVR. The transaction is expected to close in the third quarter this year. VERVE-102 currently "is being evaluated in a Phase 1b clinical trial study and has been granted Fast Track designation by the U.S. Food and Drug Administration," Lilly said. "Verve was founded with one mission in mind: transform the treatment of cardiovascular disease from chronic care to a one-dose future," Verve CEO Dr. Sekar Kathiresan said. "In just seven years, our team has progressed three in vivo gene editing products, with two currently in the clinic. Now, we will take the next steps in the drug development journey together with an ideal strategic partner in Lilly." The Financial Times reported late Monday that the companies were close to a deal. Eli Lilly shares, which entered Tuesday up roughly 5% this year, were down less than 1% in recent trading. With today's sharp gains, Verve stock has nearly doubled in 2025. UPDATE—This article has been updated with the latest share price information. Read the original article on Investopedia
Yahoo
9 hours ago
- Yahoo
Lilly to acquire Verve in $1B bet on gene editing for heart disease
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Eli Lilly agreed to buy Verve Therapeutics for $1 billion, betting on the promise of one-and-done gene therapies to treat cardiovascular disease. The deal announced Tuesday offers Verve stockholders $10.50 a share, plus a contingent value right worth another $3 a share. The non-tradeable CVR would pay out if the company's experimental VERVE-102 treatment advances enough to dose a patient in a Phase 3 trial within 10 years of the transaction's closing. Verve CEO Sekar Kathiresan and other top stockholders have already agreed to tender shares that represent about 17.8% of Verve's outstanding stock and the gene editing company's board recommends that all investors agree to the tender offer, Lilly said. A second-step merger will follow if needed. The companies expect to complete the transaction in the third quarter. For Lilly, the acquisition offers greater control of a pipeline it's already invested in. The company inked a deal with Verve in 2023 to develop a product now known as VERVE-301 that's still in preclinical research. Later that year, Lilly bought other Verve opt-in rights from Beam Therapeutics that include the program for VERVE-102. 'The deal makes sense for Verve shareholders and makes sense given the exposure Lilly has to Verve's entire disclosed pipeline,' William Blair analyst Myles Minter wrote in a note to clients. Lilly is also stepping in at a time when Verve shares are undervalued, Minter said. Verve went public in 2021 with one of the largest initial offerings of the year in the biotech industry, raising almost $270 million by selling shares at $19 each. As an investment boom continued that year amid high hopes for gene therapies, Verve's shares soared above $70. But the company's lead product, VERVE-101, encountered safety concerns and Verve decided to scrap it in favor of a successor, VERVE-102, that used a different lipid nanoparticle for delivery of the treatment. That product has shown early promise. Even so, Verve shares closed at $6.27 yesterday, hurt by a general slump in investment in cell and gene therapy companies. 'Eli Lilly is getting a bargain here,' Minter wrote. Still, the 67% premium to the current share price is 'a win for Verve shareholders and the gene editing space more broadly, which has been under significant macro pressure in a difficult funding environment.' The CVR is likely to pay out, Minter said. The timeframe of 10 years shouldn't be an issue; dosing in a Phase 3 trial is more dependent on continued demonstration of safety in earlier-stage research, he wrote. The larger question for Lilly is whether patients and doctors will embrace genetic medicines for cardiovascular disease, when more traditional treatment options are readily available. Other companies have struggled in that situation. Verve counters that many patients drop off standard medications, putting themselves in danger of complications like a heart attack. The company's lead product is administered as an infusion, which also sets it apart from the complicated administration process that underlies high-profile gene editing treatments such as Vertex's Casgevy. Verve's medicine 'could shift the treatment paradigm for cardiovascular disease from chronic care to one-and-done treatment,' Ruth Gimeno, Lilly's group vice president for diabetes and metabolic research and development, said in the company's press release. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
